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Introduction
Pulmonary hypertension (PH) is a severe form of pulmonary vas-
cular disease that results in death in up to two-thirds of affected 
patients within 5 years of diagnosis. There are 5 World Health 
Organization subtypes of PH. Group 3 PH, the second deadliest 
category of PH, is caused by hypoxemia resulting from devel-
opmental lung disorders such as bronchopulmonary dysplasia 
(BPD), chronic obstructive lung disease (COPD), combined pul-
monary fibrosis and emphysema (CPFE), interstitial lung disease, 
alveolar hypoventilation disorders, or high altitude (1, 2).
PH increases the morbidity and mortality in patients with 
COPD, BPD, and CPFE (3–5). Preterm birth affects more than 
500,000 babies born in the United States each year and BPD is 
the most common complication in preterm infants born before 
29 weeks of gestation (3). Up to half of preterm infants with BPD 
and PH die within 2 years of diagnosis (3). Five to ten percent of 
patients with COPD are diagnosed with PH, and up to 64% of these 
patients will die within 5 years (4, 6). First described by Cottin 
et al., CPFE is characterized by a history of heavy smoking, exer-
cise hypoxemia, upper lobe emphysema, lower lobe fibrosis, 
abnormally low lung volumes, and severely reduced carbon mon-
oxide transfer (7). Between 47% and 90% of patients with CPFE 
develop PH (6, 8) and most will develop moderate to severe PH (9). 
PH contributes to the dysfunction of patients with CPFE including 
severe dyspnea, markedly impaired transfer of gas, and exercise 
hypoxemia, ultimately resulting in a poorer prognosis (10). An 
estimated 1-year survival rate of 60% was reported in patients 
with both CPFE and PH (8).
PH is characterized by pathologic changes in endothelial cell 
(EC) and vascular wall function. In response to pathologic stimu-
li such as hypoxia, hyperplasia of vascular smooth muscle (VSM) 
increases pulmonary vascular pressure (11–15). EC dysfunction, 
excessive vascular remodeling, and inflammation contribute to 
progressive elevation of pulmonary vascular resistance, leading to 
increased right ventricular (RV) afterload. The histopathology of 
PH is well documented, but the molecular mechanisms underly-
ing the vascular remodeling are poorly understood.
Sustained increase in RV afterload ultimately results in right 
heart failure. Current pharmacological treatments focused on 
vasodilation for symptomatic relief have limited effects on vascu-
lar remodeling. Research has led to drugs that have significantly 
decreased morbidity and prolonged life expectancy in patients 
with Group 1 PH. Only some of these drugs show benefit to 
patients with Group 3 PH (6, 16, 17). A mechanistic understanding 
of the pulmonary vascular remodeling in Group 3 PH is thus nec-
essary to identify noninvasive diagnostic tools for early detection 
of cardiopulmonary compromise, to develop effective therapies, 
to monitor treatment response, and to improve overall outcome.
Endothelial-mesenchymal transition (EndMT) is a form of 
cellular plasticity described as the ability of ECs to dedifferentiate 
into a multipotent mesenchymal progenitor. EndMT begins with a 
morphological change from a classical cobblestone-like structure 
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or hematopoietic homeostasis; however, when challenged with 
skin, retina, or ischemia-reperfusion heart injury, mice lacking EC 
FGFR1/2 displayed impaired neovascular growth and tissue repair 
(39, 40). Additionally, loss of EC FGFR1 activity caused increased 
neointimal thickness in a vein graft model (41). Studies investigat-
ing the role of FGFR signaling in EndMT have demonstrated inter-
actions between FGFR and TGF-β signal transduction pathways 
(42). Hence, we hypothesize that EC FGFR1/2 signaling promotes 
EC signals that protect against PH.
To investigate the function of EC FGFR signaling in the 
pathogenesis of PH, we examined the response of mice lacking 
EC FGFR1/2 or mice in which EC FGFR1 signaling was activated 
through 2 weeks of chronic hypoxia. We found that mice deficient 
in EC FGFR signaling developed more severe PH, whereas mice 
in which FGFR1 signaling was activated in ECs developed less 
severe PH. Furthermore, we show that the lack of EC FGFR1/ 
2 signaling augmented EndMT changes in vivo and increased 
TGF-β/Smad2/3 signaling. We found that activation of EC 
FGFR1 signaling repressed EndMT. These studies establish 
the importance of EC FGFR signaling in the pathogenesis of 
hypoxia-induced PH and suggest the possibility of future FGF 
pathway–based therapeutics aimed at reducing the severity of PH 
in hypoxia-challenged patients.
Results
FGFR1 and FGFR2 inactivation in ECs worsens in vivo hypoxia- 
 PH. To determine the effect of hypoxia on Fgf2 expression, 
6-week-old mice were challenged with hypoxia (10% FiO2) 
for 2 weeks. Quantitative real-time PCR (qRT-PCR) analysis of 
whole lungs from mice exposed to 2 weeks of hypoxia or normoxia 
showed increased expression of Fgf2 (Figure 1A). To ascertain 
the requirements for FGF signaling in ECs in response to hypox-
ia, 6-week-old Flk1(Vegfr2/Kdr)Cre; Fgfr1fl/fl; Fgfr2fl/fl (FLK1-DCKO) 
and Flk1Cre or Fgfr1fl/fl; Fgfr2fl/fl (control) mice were challenged with 
hypoxia for 2 weeks. Cardiac catheterization was used to measure 
RV pressure (RVp) as a surrogate for pulmonary arterial pressure. 
Compared with control mice in normoxia, littermates in hypoxia 
demonstrated significant increases in RVp (Figure 1B) and the RV 
to left ventricle plus septum weight ratio (Figure 1, C and D), con-
sistent with development of PH and RV hypertrophy, respective-
ly. Hypoxia-exposed FLK1-DCKO mice (hFLK1-DCKO) showed 
further elevation in RVp (by 24.4%, P < 0.05) (Figure 1B) and an 
increased RV to left ventricle plus septum weight ratio as com-
pared with controls (hControl; Figure 1, C and D), demonstrating 
worsening PH in the absence of EC FGF signaling. Flk1Cre (a knock-
in mutation at the Vegfr2/Kdr locus) and wild-type mice under 
normoxic conditions did not show any difference in RVp (Sup-
plemental Figure 1A; supplemental material available online 
with this article; https://doi.org/10.1172/JCI141467DS1). Hypox-
ia-challenged Flk1Cre and wild-type mice also did not show any 
difference in RVp (Supplemental Figure 1B).
The echocardiographic imaging marker, pulmonary artery 
acceleration time (PAAT), has been validated for detection of 
pulmonary vascular disease and PH in mice (43). Comparison 
of echocardiographic and cardiac catheterization measures 
showed a strong correlation of PAAT (Figure 1E) and PAAT nor-
malized to RV ejection time (PAAT/RVET) (Figure 1F) with RVp 
to an elongated, spindle shape. The process further undergoes a 
loss of cell-cell adhesion, dissociation from the basement mem-
brane, and migration into the medial layer. EndMT is involved in 
normal vascular development and several pathologies, including 
pulmonary arterial hypertension (PAH, also known as Group 1 
PH), atherosclerosis, and tumor angiogenesis (18–20). EndMT 
is regulated by a common set of physiological effectors, includ-
ing hypoxia, inflammation, and shear stress (21), and molecular 
effectors, including transforming growth factor β (TGF-β) and 
fibroblast growth factor (FGF) (19). Inflammation facilitates 
EndMT in a TGF-β–dependent manner (11), and shear stress 
downregulates FGF receptor (FGFR) signaling and enhances 
nuclear localization of TGF-β–activated Smad2/3 (21). EndMT is 
characterized by reduced production of EC proteins such as plate-
let EC adhesion molecule-1 (PECAM1, CD31) and vascular endo-
thelial cadherin (VE-cadherin, CDH5), accompanied by a con-
comitant increase in production of mesenchymal markers such 
as α-smooth muscle actin (αSMA, ACTA2), fibronectin (FN1), and 
vimentin (VIM) (22).
The TGF-β family consists of a group of multifunctional cyto-
kines that signal via type 1 and type 2 Ser/Thr kinase receptors and 
Smad transcription factors (23). Upon TGF-β activation, receptor- 
regulated Smad2 and Smad3 become phosphorylated, translo-
cate to the nucleus, and in combination with other transcription 
factors regulate gene expression. TGF-β–induced phosphorylated- 
Smad2/3 (p-Smad2/3) nuclear accumulation is enhanced by 
hypoxic conditions (24). TGF-β2 stimulates EndMT by signal-
ing through canonical Smad2/3 and noncanonical pathways (18). 
Activation of the Smad2/3 pathway leads to overexpression of 
Twist (TWIST1 and TWIST2), Snail (SNAI1), and Slug (SNAI2) 
transcription factors (25–27). The TWIST family are a group of 
helix-loop-helix transcription factors that can bind DNA E-boxes 
to regulate transcription (28). Among the EndMT target genes 
upregulated by hypoxia, SNAI1 was identified as a master regu-
lator (29). The SNAI1 family of zinc finger transcription factors 
share a highly conserved C-terminal region required for transcrip-
tional repressor activity and a posttranslationally modifiable cen-
tral domain that can regulate protein stability or localization (30). 
TGF-β–mediated EndMT can also be modulated by FGF signaling 
through FGFRs and the adaptor molecule FRS2. Knocking down 
FRS2 in human umbilical vein endothelial cells (HUVECs) caused 
an increase in the production of αSMA and vimentin (31). Inde-
pendent of TGF-β, loss of BMPR2 can also induce gene expression 
changes consistent with EndMT (32). TGF-β has been shown to 
induce EndMT in PAH (20); however, its role in Group 3 PH has 
not been established.
FGF2 and FGFR1/2 protein levels are elevated in lung tissue 
samples from patients with PH (33–35). Additionally, FGF2 is ele-
vated in a mouse model of Group 3 PH where mice are exposed to 
chronic hypoxia (36, 37) and in vitro in human ECs cultured under 
hypoxic conditions (38). Changes in the expression of both ligand 
and receptors suggest that there may be functional consequences 
of this signaling pathway in the pathogenesis of PH. To study the 
role of FGFR signaling in ECs in vivo, mouse models have been 
generated that lack EC FGFR1 and FGFR2 (39, 40). Studies of 
these mice show that EC FGFR1 and FGFR2 are dispensable for 
mouse embryonic development and are not required for vascular 
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control mice in normoxia, littermates in hypoxia demonstrated 
significant increase in medial areas of both smaller caliber, dis-
tal vessels (20–50 μm, Figure 2B) and larger caliber, proximal 
vessels (50–100 μm, Figure 2C). FLK1-DCKO mice showed 
further increases in the vascular medial area as compared with 
controls (Figure 2, A–C), demonstrating more severe pulmo-
nary vascular remodeling. To assess neomuscularization, lung 
tissue sections were coimmunostained with antibodies against 
PECAM1 and αSMA to identify ECs and VSM, respectively. 
Hypoxia reduced the proportion of nonmuscularized and par-
tially muscularized vessels and increased the proportion of 
fully muscularized vessels as compared with normoxia controls 
in hypoxia-challenged mice. PAAT was decreased in control 
hypoxia-exposed mice compared with normoxia controls and 
FLK1-DCKO mice showed a further decrease when compared 
with control mice in hypoxia (Figure 1G). The PAAT/RVET 
ratio showed a significant decrease in hypoxia compared with 
normoxia-exposed mice and FLK1-DCKO mice showed a fur-
ther decrease in these measures after 2 weeks in hypoxia (Fig-
ure 1H). Therefore, loss of EC FGFR signaling is sufficient to 
increase hypoxia-induced PH.
Histologic analyses of the pulmonary arteries showed 
increased medial thickening in control mice in hypoxia as com-
pared with littermates in normoxia (Figure 2A). Compared with 
Figure 1. Increased severity of pulmonary 
hypertension in mice lacking endothelial 
FGFR1 and FGFR2. Pulmonary hypertension 
assessment after 2 weeks of hypoxia expo-
sure (white column) compared with normox-
ia controls (gray column). (A) Quantitative 
RT-PCR showing Fgf2 expression in whole 
lungs from wild-type mice, n = 4. Statistical 
significance was determined by 2-tailed, 
unpaired Student’s t test. (B) RV pressures 
determined by cardiac catheterization of 
hypoxia-challenged control (Flk1Cre or Fgfr1fl/fl;  
Fgfr2fl/fl) and FLK1-DCKO mice compared with 
littermates in normoxia, n = 7–13. (C) RV to 
left ventricular plus septal (RV/LV+S)  
weight comparison between hypoxia- 
exposed control and FLK1-DCKO mice 
compared with littermates in normoxia, n = 
4–6. (D) Representative specimens of whole 
hearts. Scale bar: 10 mm. (E) Correlation plot 
of right heart catheterization–derived pulmo-
nary hemodynamics and pulmonary artery 
acceleration time (PAAT) from all mice  
(normoxia and hypoxia), n = 26. (F) Correla-
tion plot of right heart catheterization–
derived pulmonary hemodynamics and PAAT/
RV ejection time ratio (PAAT/RVET), n = 26. 
(G and H) Comparison of PAAT (G) and PAAT/
RVET (H) in hypoxia-challenged FLK1-DCKO 
and control mice, n = 4–10. Statistical sig-
nificance was determined by 2-way ANOVA 
with Holm-Šídák multiple comparison test. 
All data are shown as the mean ± SEM. *P < 
0.05, **P < 0.01. Closed circles, control mice 
in normoxia (nControl); open circles, control 
mice in hypoxia (hControl); closed squares, 
FLK1-DCKO mice in normoxia (nFLK1-DCKO); 
open squares, FLK1-DCKO mice in hypoxia 
(hFLK1-DCKO). 
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(Figure 2D). FLK1-DCKO mice showed a 
further increase in the proportion of fully 
muscularized vessels when compared with 
control littermates in hypoxia (Figure 2D). 
Thus, loss of EC FGFR signaling augments 
vascular changes associated with hypoxia- 
induced PH.
To rule out potential developmental 
effects due to constitutive loss of EC Fgfr1 
and Fgfr2 and heterozygosity of Vegfr2 
(Flk1Cre) on PH pathology, the conditional 
Cdh5-CreERT2 transgenic allele was used 
to inactivate Fgfr1 and Fgfr2 and activate the 
ROSAtdTomato lineage reporter in ECs of juve-
nile mice. Three-week-old Cdh5-CreERT2; 
Fgfr1fl/fl; Fgfr2fl/fl; ROSAtdTomato (Cdh5-DCKO) 
and control Fgfr1fl/fl; Fgfr2fl/fl (control) mice 
were treated with tamoxifen from 3–4 
weeks of age (Figure 3A). Lineage analysis 
showed colabeling of PECAM1 and tdTo-
mato fluorescence, confirming EC target-
ing by tamoxifen-treated Cdh5-CreERT2; 
ROSAtdTomato mice (Figure 3B). Transcrip-
tional analysis of pulmonary ECs isolated 
from mouse lungs using flow cytometry 
showed that Fgfr1 (Figure 3C) and Fgfr2 
(Figure 3D) expression was significantly 
decreased. Cdh5-DCKO mice were chal-
lenged with hypoxia for 2 weeks, followed 
by cardiac catheterization to measure RVp. 
Compared with control mice exposed to 
hypoxia, Cdh5-DCKO mice demonstrated 
significant increases in RVp (by 13.2%, P < 
0.05) (Figure 3E). These results show that 
loss of EC FGFR1 and FGFR2 beginning at 3 
weeks of age worsens hypoxia-induced PH, 
similar to FLK1-DCKO mice.
FGFR1 activation in ECs prevents hypoxia- 
induced PH. Because loss of EC Fgfr1 and 
Fgfr2 leads to VSM thickening in response to 
hypoxia, we hypothesized that expression of 
a constitutively active FGFR1 (caFGFR1) in 
ECs would protect against maladaptive ves-
sel muscularization in hypoxia-induced PH. 
To investigate the cell-autonomous function 
of FGF signaling in ECs, we utilized the 
Tie2-Cre transgenic allele to target the dox-
ycycline-inducible TET-on Cre-regulatable 
ROSArtTA allele, and a chimeric constitutively 
active Fgfr1 transgenic allele (TRE-caFgfr1) 
in ECs. We generated Tie2-Cre; ROSArtTA; 
TRE-caFgfr1 (caFGFR1) triple-transgenic 
mice (Figure 4A) to conditionally activate 
EC FGFR signaling. Doxycycline treat-
ment, starting at 4 weeks of age for 2 weeks, 
increased caFGFR1 expression in lungs of 
caFGFR1 compared with control mice (Fig-
Figure 2. Histologic analysis of the pulmonary vasculature in mice lacking endothelial FGFR1 and 
FGFR2. (A) Smooth muscle actin (αSMA) immunostaining of representative lungs from control and 
FLK1-DCKO mice in normoxia and hypoxia. Scale bars: 1 mm and 50 μm (insets). (B and C) Vessel wall 
thickening as assessed by medial cross-sectional area normalized to total vessel cross-sectional area 
(medial/CSA) for (B) distal vessels (20–50 μm) and (C) proximal vessels (50–100 μm), n = 4–5. (D) 
Quantification of the percentage of muscularized vessels compared with total number of vessels, in 
normoxia- and hypoxia-exposed control and FLK1-DCKO mice, n = 4–5. Statistical significance was 
determined by 2-way ANOVA with Holm-Šídák multiple comparison test. All data are shown as the 
mean ± SEM. *P < 0.05, **P < 0.01. Closed circles, control mice in normoxia (nControl); open circles, 
control mice in hypoxia (hControl); closed squares, FLK1-DCKO mice in normoxia (nFLK1-DCKO); open 
squares, FLK1-DCKO mice in hypoxia (hFLK1-DCKO).
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caliber vessels was modestly increased (1.6-fold) when comparing 
caFGFR1 mice in hypoxia versus normoxia; however, the medial 
area of large caliber vessels was still much reduced compared with 
control mice in hypoxia (4.0-fold) (Figure 5C).
To assess neomuscularization, lung tissue sections were 
coimmunostained for PECAM1 and αSMA to identify ECs and 
VSM cells, respectively. In normoxia, caFGFR1 and control mice 
showed no difference in the proportions of nonmuscularized, 
partially muscularized, and fully muscularized vessels (Figure 
5D). In response to hypoxia, control mice demonstrated a signifi-
cant reduction in the proportion of nonmuscularized and partially 
muscularized vessels, and an increase in the proportion of fully 
muscularized vessels (Figure 5D). However, in response to hypox-
ia, caFGFR1 mice showed similar proportions of vessel muscu-
larization to those of mice in normoxia, and a significantly lower 
proportion of fully muscularized vessels compared with hypoxia- 
exposed control mice (Figure 5D). These results demonstrate that 
EC FGFR1 activity reduces histologic changes in the vasculature 
associated with hypoxia-induced PH.
FGF signaling reduces hypoxia-induced EndMT. Reprograming 
of ECs to VSM (Figure 6A), a process known as EndMT, under-
lies several disease pathologies (18–20). To evaluate the effect of 
hypoxia on EndMT, Tie2-Cre; ROSAtdTomato EC-lineage report-
er mice were exposed to hypoxia (Figure 6B). After 2 weeks in 
hypoxia, VSM cells in the tunica media layer were found to express 
the tdTomato EC-lineage tag (Figure 6B), indicating an EndMT 
response to hypoxic conditions. Normoxia control mice showed 
no tdTomato fluorescence in αSMA-positive cells. Hypoxia- 
exposed control mice were also coimmunostained for PECAM1 and 
αSMA to demonstrate EndMT (Figure 6C). VSM cells in the medial 
ure 4B). In prior studies, induction of caFGFR1 in ECs for 1 month 
did not have any apparent adverse effects (44).
Four-week-old caFGFR1 and control mice were placed on dox-
ycycline chow. Starting at 6 weeks of age, mice were challenged 
with hypoxia for 2 weeks, followed by cardiac catheterization to 
measure RVp. In response to hypoxia, control mice demonstrated 
significant increases in RVp (Figure 4C) and the RV to left ventri-
cle plus septum weight ratio (Figure 4, D and E), consistent with 
development of PH. At baseline, caFGFR1 mice compared with 
control mice in normoxia showed no difference in RVp (Figure 4C) 
and the RV to left ventricle plus septum weight ratio (Figure 4D). 
However, in response to hypoxia, caFGFR1 mice showed similar 
RVp and RV to left ventricle plus septum weight ratio compared 
to normoxia mice, and significantly lowered RVp (by 23.7%, P < 
0.05) and RV to left ventricle plus septum weight ratio compared 
with hypoxia-exposed control mice (Figure 4, C and D). There-
fore, activation of EC FGFR1 signaling is sufficient to prevent 
hypoxia-induced PH.
Effects of hypoxia on the pulmonary vasculature of caFGFR1 
mice were consistent with resistance to the development of PH 
(Figure 5A). In normoxia, caFGFR1 mice and control mice showed 
no difference in the medial area of both smaller caliber distal ves-
sels (20–50 μm, Figure 5B) and larger caliber proximal vessels 
(50–100 μm, Figure 5C). In response to hypoxia, control mice 
demonstrated significant increases in the medial area of both 
large and small caliber vessels (Figure 5, B and C). However, in 
response to hypoxia, caFGFR1 mice showed similar medial areas 
of small caliber vessels to those of mice in normoxia and no differ-
ence in the medial area of smaller caliber vessels in caFGFR1 mice 
in hypoxia versus normoxia (Figure 5B). The medial area of large 
Figure 3. Effects of conditional deletion of Fgfr1  
and Fgfr2 in endothelial cells on hypoxia-induced 
pulmonary hypertension. (A) Experimental strat-
egy for tamoxifen-induced Cdh5-targeted deletion 
of Fgfr1 and Fgfr2 in endothelial cells (ECs). (B) 
Tamoxifen-induced Cdh5-targeted tdTomato (red) 
expression in ECs (PECAM1, green, arrowheads). 
Scale bars: 25 μm and 20 μm (insets). (C and D) 
Quantitative RT-PCR showing reduction of Fgfr1 
and Fgfr2 expression in pulmonary ECs of tamox-
ifen-treated (Cdh5-DCKO) mice compared with 
control littermates, n = 5–6. Statistical significance 
was determined by 2-tailed, unpaired Student’s 
t test. (E) RV pressures determined by cardiac 
catheterization of hypoxia-challenged control and 
Cdh5-DCKO mice, n = 7–17. Statistical significance 
was determined by 2-way ANOVA with Holm-Šídák 
multiple comparison test. All data are shown as the 
mean ± SEM. *P < 0.01, **P < 0.05. Closed circles, 
control mice in normoxia (nControl); open circles, 
control mice in hypoxia (hControl); closed squares, 
Cdh5-DCKO mice in normoxia (nCdh5-DCKO); open 
squares, Cdh5-DCKO mice in hypoxia (hCdh5-DCKO).
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layer expressed the endothelial marker PECAM1 (Figure 6C), fur-
ther supporting an EndMT response to hypoxic conditions.
To determine whether loss of FGFR1 and FGFR2 signaling 
in EC affects EndMT, Fgfr1fl/fl; Fgfr2fl/fl control and Flk1Cre; Fgfr1fl/fl; 
Fgfr2fl/fl; ROSAtdTomato (FLK1-DCKO/Tomato) mice were examined. 
In normoxia, control and FLK1-DCKO/Tomato mice did not show 
any difference in the proportion of VSM cells with the tdTomato 
EC-lineage tag (Figure 7A). In mice exposed to hypoxia, control 
mice showed a significant increase in the percentage of EC lin-
eage–tagged VSM cells compared with normoxia, and hypoxia- 
exposed FLK1-DCKO/Tomato mice demonstrated a further 
increase in the percentage of VSM cells derived from the EC lin-
eage (Figure 7A). To determine the effects of activation of FGFR1 
signaling on EndMT, we used the caFGFR1 mouse model. Four-
week-old caFGFR1 and control mice were placed on doxycycline 
chow. Starting at 6 weeks of age, mice were challenged with 
hypoxia for 2 weeks. Under normoxic conditions, caFGFR1 and 
control mice did not show any difference in the proportion of VSM 
cells derived from the EC lineage (Figure 7B). Relative to mice in 
normoxia, control mice exposed to hypoxia showed a significant 
increase in the percentage of VSM cells derived from the EC lin-
eage. Compared with control mice in hypoxia, caFGFR1 mice in 
hypoxia showed a significant reduction in EndMT (Figure 7B), 
indicating that activation of FGFR1 in ECs inhibits EndMT.
FLK1-DCKO/Tomato and Fgfr1fl/fl; Fgfr2fl/fl control mice 
were also coimmunostained for PECAM1 and αSMA to demon-
strate EndMT. In normoxia, FLK1-DCKO mice did not show any 
difference in the proportion of VSM cells expressing PECAM1 
(Figure 7C). In mice exposed to hypoxia, control mice showed 
a significant increase in the percentage of PECAM1-express-
ing VSM cells compared with normoxia, and hypoxia-exposed 
FLK1-DCKO demonstrated a further increase in the percentage 
of VSM cells expressing the EC marker, PECAM1 (Figure 7C). 
Under normoxic conditions, caFGFR1 and control mice did not 
show any difference in the proportion of VSM cells expressing 
PECAM1 (Figure 7D). Control mice exposed to hypoxia showed 
a significant increase in the percentage of VSM cells expressing 
PECAM1, compared with mice in normoxia. Relative to control 
mice in hypoxia, caFGFR1 mice in hypoxia showed a significant 
reduction in EndMT (Figure 7D), further demonstrating that EC 
FGFR1 activation inhibits EndMT.
FGF signaling inhibits the TGF-β pathway response to hypoxia 
in vivo. TGF-β signaling regulates EndMT in Group 1 PAH and 
atherosclerosis (20, 45). To evaluate the effect of EC Fgfr1 and 
Fgfr2 deletion on TGF-β signaling, qRT-PCR analysis was per-
formed on RNA from whole lungs of FLK1-DCKO and control 
mice exposed to 2 weeks of hypoxia or normoxia. In normoxia, 
FLK1-DCKO mice did not show any differences in expression of 
TGF-β pathway components compared to controls (Figure 8A). 
FLK1-DCKO mice in hypoxia demonstrated increased expres-
sion of Tgfbr2, Snai1, Snai2, Twist1, and Acta2 and decreased 
expression of Pecam1 (Figure 8A). Tgfb1 and Tgfb2 ligand expres-
sion was decreased in hypoxia-exposed FLK1-DCKO mice com-
pared with controls (Supplemental Figure 2). FLK1-DCKO mice 
Figure 4. Effects of cell-autonomous activation 
of FGFR1 in endothelial cells on the develop-
ment of hypoxia-induced pulmonary hyperten-
sion. (A) Experimental strategy for expressing 
the tetracycline-inducible constitutively active 
FGFR1 (caFGFR1) in endothelial cells (ECs).  
Tie2-Cre; ROSArtTA results in reverse tetracycline- 
controlled transactivator (rtTA) expression in ECs 
(blue arrow), and in the presence of doxycycline 
(green box), TRE-caFGFR1 expression is induced 
in ECs (TIE2-caFGFR1 = Tie2-Cre; ROSArtTA; 
TRE-caFgfr1). (B) Quantitative RT-PCR showing 
induction of caFGFR1 expression in lungs of dox-
ycycline-treated compared with untreated mice, 
n = 3–4. Statistical significance was determined 
by 2-tailed, unpaired Student’s t test. (C) RV 
pressures determined by cardiac catheterization 
of hypoxia-challenged control and caFGFR1 mice, 
n = 4–15. (D) Right ventricular to left ventricu-
lar plus septal (RV/LV+S) weight comparison 
between control and caFGFR1 mice, n = 4. (E) 
Representative whole hearts. Scale bar: 10 mm. 
Statistical significance was determined by 2-way 
ANOVA with Holm-Šídák multiple comparison 
test. All data are shown as the mean ± SEM.  
NS, not significant. *P < 0.05, **P < 0.01.  
caFGFR1 = Tie2-Cre; ROSArtTA; TRE-caFgfr1.  
Closed circles, control mice in normoxia 
(nControl); open circles, control mice in hypoxia 
(hControl); closed squares, TIE2-caFGFR1 mice in 
normoxia (ncaFGFR1); open squares,  
TIE2-caFGFR1 mice in hypoxia (hcaFGFR1).
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in normoxia also did not show any differences in the expres-
sion of Fgf2 (Figure 8A). In hypoxia, control mice demonstrated 
increased Fgf2 and hypoxia-exposed FLK1-DCKO mice showed a 
further increase in Fgf2 expression.
To evaluate the effect of activation of FGFR1 signaling in 
ECs, qRT-PCR analysis was performed on RNA from whole lungs 
of caFGFR1 and control mice that were exposed to 2 weeks of 
hypoxia or normoxia. In normoxia, there was no difference in the 
expression of TGF-β pathway components in caFGFR1 and con-
trol mice (Figure 8B). In hypoxia, control mice showed increased 
expression of Tgfbr2, Snai1, Snai2, and Fgf2, while Twist1, Pecam1, 
and Acta2 expression was not changed. However, in hypoxia, com-
pared with controls, caFGFR1 mice showed lower levels of Tgfbr2, 
Snai1, Snai2, Twist1, and Fgf2, and similar levels of Pecam1 and 
Acta2. Tgfb1 and Tgfb2 ligand expression was decreased in hypoxia- 
exposed caFGFR1 mice compared with controls (Supplemental 
Figure 2). Notably, caFGFR1 mice in normoxia did not show any 
differences in expression of Fgf2, whereas control mice in hypoxia 
showed significantly higher levels of Fgf2 (Figure 8B).
To directly assess TGF-β signaling in vivo, we immunostained 
lung tissue for p-Smad2/3 in both mouse models. In control lungs, 
hypoxia exposure increased p-Smad2/3 compared with normoxia 
(Figure 9). Under hypoxic conditions, FLK1-DCKO mice showed 
a further increase in the percentage of p-Smad2/3–expressing 
ECs compared with control mice (Figure 9A) and caFGFR1 mice 
showed less p-Smad2/3 expression in ECs (Figure 9B). These 
results demonstrate that FGF signaling suppresses TGF-β signal-
ing and EndMT in response to hypoxia.
FGF inhibition promotes EndMT in vitro. To directly assess 
the effects of FGF inhibition on EndMT, human pulmonary 
artery ECs (HPAECs) were cultured in hypoxia (5% O2) for 48 
hours (Figure 10A) or 14 days (Figure 10B), and then assayed for 
changes in RNA expression of TGF-β pathway components and 
markers of EndMT. After 48 hours, treatment with the FGF inhib-
itor BGJ398 (infigratinib) under normoxic conditions increased 
Tgfb2 21-fold, increased Acta2 and Fgf2, and decreased Cdh5, 
but did not change the expression of the transcription factors 
Snai2 and Twist1 and the mesenchymal marker Vim. FGF inhibi-
tion under hypoxic conditions increased Tgfb2 (40-fold), Snai2, 
and Twist1, and decreased Cdh5. Expression of Acta2 and Fgf2 
trended toward an increase.
HPAECs were then cultured for 14 days to evaluate the effects 
of chronic hypoxia and FGF inhibition on EndMT in vitro (Figure 
10B). In normoxia, FGF inhibition with BGJ398 did not exert any 
significant effects on expression of Tgfb2, Snai2, Twist1, Cdh5, or 
Vim, whereas expression of Fgf2 was increased and Acta2 trended 
toward an increase. However, when cultured in hypoxia, 
BGJ398-treated HPAECs demonstrated increased expression of 
Figure 5. Constitutively active FGFR1 reduces the pulmonary vascular 
response to hypoxia. (A) Smooth muscle actin (αSMA) immunostain-
ing of representative lungs from control and caFGFR1 mice in normoxia 
and hypoxia. Scale bars: 1 mm and 50 μm (insets). (B and C) Vessel wall 
thickening as assessed by medial cross-sectional area normalized to total 
vessel cross-sectional area (medial/CSA) for (B) distal vessels (20–50 
μm) and (C) proximal vessels (50–100 μm), n = 4. (D) Quantification of the 
percentage of muscularized vessels compared with total number of ves-
sels, in normoxia- and hypoxia-exposed control and caFGFR1 mice, n = 4. 
Statistical significance was determined by 2-way ANOVA with Holm-Šídák 
multiple comparison test. All data are shown as the mean ± SEM. NS, not 
significant. *P < 0.05, **P < 0.01. caFGFR1 was induced as shown in Figure 
4A. Closed circles, control mice in normoxia (nControl); open circles, control 
mice in hypoxia (hControl); closed squares, TIE2-caFGFR1 mice in normoxia 
(ncaFGFR1); open squares, caFGFR1 mice in hypoxia (hcaFGFR1).
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strating EndMT in vitro (Figure 11A). Quantitative anal-
yses showed an increased number of colonies of αSMA- 
positive cells per well in BGJ398-treated hypoxia-exposed 
HPAECs, and no colonies in untreated or normoxia- 
cultured wells (Figure 11B). Western blot analysis showed 
no difference in Smad2/3 phosphorylation or ACTA2 
expression in normoxia. BGJ398 treatment increased 
Smad2/3 phosphorylation and αSMA expression in 
hypoxia-exposed HPAECs (Figure 11, C and D). These 
data demonstrate that, in response to hypoxia, EndMT 
activity and TGF-β signaling are increased when FGF sig-
naling is inhibited (Figure 11, D and E).
EndMT observed in patients with CPFE and PH. Group 
3 PH can be caused by hypoxia resulting from lung dis-
orders such as COPD, BPD, or CPFE (1, 2). To evaluate 
the presence of molecules known to mediate EndMT in 
CPFE, we assessed histological sections of lungs from 
patients with CPFE in comparison with normal lung 
tissue. Patients with CPFE had average mean pulmo-
nary artery pressure of 31 mmHg (Supplemental Table 
1), above the diagnostic criteria of 25 mmHg for PH. To 
assess FGF and TGF-β signaling, we examined expres-
sion of ETV5 and p-Smad2/3, respectively. Compared 
with controls, lung tissue sections from patients with 
CPFE showed decreased immunostaining for ETV5 (Fig-
ure 12A). In normal lung tissue, an average of 95% of 
CDH5-positive ECs were positive for ETV5, compared 
with 73% in CPFE lung tissue (Figure 12C). Immunos-
taining for p-Smad2/3 showed increased expression 
in CPFE lung tissue compared with normal lung tissue 
(Figure 12B). In normal lung tissue, an average of 50% of 
CDH5-positive ECs were positive for p-Smad2/3, com-
pared with 64% of CDH5-positive ECs that were positive 
for p-Smad2/3 in CPFE lung tissue (Figure 12D). These 
data correlate pulmonary pathologies such as CPFE that 
contribute to Group 3 PH with reduced FGF signaling and 
increased TGF-β signaling, similarly to experimental con-
ditions that promote EndMT such as chronic hypoxia.
Discussion
The results of this study support a role for EC FGFR 
signaling as a modulator of the EndMT response in the 
pathogenesis of hypoxia-induced PH. We showed that 
in response to chronic hypoxia, (a) loss of EC FGFR1 and 
FGFR2 signaling increased PH, (b) activation of FGFR1 
in ECs prevented PH, (c) EC FGFR signaling attenuated 
the TGF-β signaling pathway, and (d) FGFR signaling was reduced 
and TGF-β signaling was activated in lung tissue from patients 
with CPFE. Taken together, these results establish a link between 
hypoxia, the loss of protective EC FGFR signaling input, and the 
induction of EndMT, which ultimately plays an important role in 
the pathogenesis of hypoxia-induced PH.
FGFR1 is robustly expressed, while FGFR2 and -3 are 
expressed at lower levels in normal ECs (40, 41, 46–48). Under 
homeostatic conditions, inactivation of EC Fgfr1 and Fgfr2 did 
not cause any overt developmental or homeostatic defects. 
However, several studies showed that loss or inhibition of these 
Tgfb2, Twist1, and Acta2, a trend toward increased expression of 
Snai2 and Fgf2, and decreased expression of Cdh5 (Figure 10B). 
Notably, chronic hypoxia increased expression of Fgf2 and down-
stream transcriptional targets of FGF signaling, ETS transcription 
variant 4 and 5 (Etv4 and Etv5), and dual-specificity phosphatase 6 
(Dusp6) (Figure 10, B and C). As expected, expression of Etv4 was 
decreased with FGFR inhibition (Supplemental Figure 4).
Compared with normoxia, exposure to 5% oxygen for 14 
days did not induce expression of αSMA in HPAECs (Figure 11A). 
However, HPAECs exposed to 5% oxygen for 14 days and treated 
with BGJ398 formed colonies of αSMA-expressing cells, demon-
Figure 6. FGFR signaling regulates endothelial-mesenchymal transition in 
hypoxia-induced pulmonary hypertension. (A) Illustration depicting the process 
of endothelial-mesenchymal transition (EndMT). (B) Lineage tracing visualized by 
immunostaining smooth muscle cells (αSMA, green) expressing endothelial origins 
(Tie2-Cre; ROSAtdTomato, red) after 2 weeks of hypoxia. Scale bars: 25 μm and 15 μm 
(insets). Inset, higher magnification image illustrating overlay of αSMA (green) and 
endothelial lineage tdTomato (red). (C) Lineage tracing visualized by immunostaining 
smooth muscle cells (αSMA, green) expressing endothelial origins (PECAM1,  
red) after 2 weeks of hypoxia. Scale bars: 25 μm and 15 μm (insets). Inset, higher 
magnification image illustrating overlay of αSMA (green) and PECAM1 (red). Arrows, 
non–endothelial origin smooth muscle cells; arrowheads, endothelium-originated 
smooth muscle cells.
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required under homeostatic conditions (39, 40). By 
contrast, under hypoxic conditions, FLK1-DCKO mice 
demonstrated increased vessel wall thickness and neo-
vascularization when compared with their littermate 
controls. These results show that loss of EC FGFR 
signaling promotes changes that are associated with 
hypoxia-induced PH.
The Flk1Cre mouse is heterozygous for Vegfr2  
(Kdr). Haploinsufficiency of Vegfr2 suppresses tumor- 
induced angiogenesis (52) and leads to increased 
infarct size in a myocardial ischemia-reperfusion inju-
ry model (53). Additionally, pharmacological inhibition 
of VEGFR is an important regulator of PH (54), and 
mice treated with the VEGFR inhibitor SU5416 exhib-
ited PH changes in response to hypoxia (55, 56). Fur-
thermore, mice heterozygous for Vegfr2 show reduced 
pathological angiogenesis (57, 58). It was therefore 
important to assess the effects of Vegfr2 haploinsuf-
ficiency on hypoxia-induced PH. Although VEGFR2 
activity is vital to vascular development (59), we did 
not observe any identifiable physiologic or histolog-
ic phenotypes in Flk1Cre and wild-type mice under 
normoxic conditions. Furthermore, we found no dif-
ference between wild-type, Flk1Cre, and FGFR1fl/fl; 
FGFR2fl/fl mice after challenge with hypoxia.
To rule out potential developmental and Vegfr2  
haploinsufficiency effects on the phenotype of FLK1-
DCKO mice, we constructed Cdh5-DCKO mice as a 
second model to inducibly inactivate Fgfr1 and Fgfr2 in 
ECs in juvenile mice. Cdh5-DCKO mice did not show 
any apparent developmental or homeostatic defects 
under normoxic conditions. However, Cdh5-DCKO 
mice demonstrated worse PH when exposed to hypox-
ia, similar to but less severe than what was observed in 
FLK1-DCKO mice. These findings further support the 
model that EC FGFR signaling in adult mice worsens 
hypoxia-induced PH.
To test whether activation of EC FGFR signal-
ing could protect against hypoxia-induced PH, we induced the 
expression of a chimeric constitutively active FGFR1 (caFGFR1) 
in ECs before and during exposure to hypoxia. Previously, we 
showed that caFGFR1 overexpression led to increased expres-
sion of downstream FGFR1 target signals and genes (44, 60, 
61). Here, we showed that with caFGFR1 induced in ECs, the 
average RVp and RV hypertrophy of caFGFR1 mice were sig-
nificantly lower than control littermates in hypoxia. In fact, the 
average RVp of the caFGFR1 group was comparable to that of 
normoxia controls. Additionally, histologic changes were lim-
ited to a moderate increase in VSM thickening of proximal, 
larger caliber vessels. Although Tie2 also targets hematopoietic 
cell lineages, we did not observe any physiologic differences 
between control and caFGFR1 mice under normoxic condi-
tions. As caFGFR1 expression was induced 2 weeks prior to and 
throughout the duration of hypoxia exposure, the absence of 
PH changes may, in part, be due to a preventive effect. To deter-
mine whether there may be a therapeutic effect of activated 
EC FGFR signaling, future studies will be required in which 
receptors in ECs leads to defective injury responses (39–41, 49). 
Based on these observations, we hypothesized that EC FGFR 
signaling would be protective against the adaptive vascular 
response to hypoxia. To test this, two models were used to inac-
tivate floxed alleles of Fgfr1 and Fgfr2 in ECs: constitutive tar-
geting with Flk1Cre (FLK1-DCKO) and inducible targeting with 
Cdh5-CreER (Cdh5-DCKO).
Group 3 PH can be modeled by placing mice in normobar-
ic chambers at 10% effective oxygen, which results in a reliable 
increase in RVp by at least 10 mmHg, RV hypertrophy, and pul-
monary vascular remodeling (50). Additionally, after exposing 
6-week-old mice to 10 days of hypoxia, pulmonary artery ves-
sel wall thickness was increased (51). To assess the in vivo role 
of FGFR signaling in the development of PH, we investigated 
the effect of loss of FGFR signaling in mice with experimental 
PH induced by hypoxia. Under normoxic conditions, inactiva-
tion of EC FGFR1/2 signaling with Flk1Cre (FLK1-DCKO) did not 
result in any identifiable physiologic or histologic phenotypes, 
consistent with previous findings that EC FGFR signaling is not 
Figure 7. FGFR signaling regulates endothelial-mesenchymal transition in hypoxia- 
induced pulmonary hypertension. Quantification of EndMT shown as a percentage 
of tdTomato+αSMA+ double-positive cells in relation to the total number of αSMA+ 
cells in (A) FLK1-DCKO mice (n = 4–6) and (B) caFGFR1 mice (n = 4–7). Quantification of 
EndMT shown as a percentage of PECAM1+αSMA+ double-positive cells in relation to 
the total number of αSMA+ cells in (C) FLK1-DCKO mice (n = 3) and (D) caFGFR1 mice 
(n = 3–4). Statistical significance was determined by 2-way ANOVA with Holm-Šídák 
multiple comparison test. All data are shown as the mean ± SEM. **P < 0.01. Closed 
circles, control mice in normoxia (nControl); open circles, control mice in hypoxia 
(hControl); closed squares, Flk1Cre; Fgfr1fl/fl; Fgfr2fl/fl mice in normoxia (nFLK1-DCKO) or 
caFGFR1 mice in normoxia (ncaFGFR1); open squares, Flk1Cre; Fgfr1fl/fl; Fgfr2fl/fl mice in 
hypoxia (hFLK1-DCKO) or caFGFR1 mice in hypoxia (hcaFGFR1).
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In contrast to the results in this study, Chang et al. showed that 
mice expressing perlecan that is deficient in heparan sulfate (HS), 
a cofactor for FGF-FGFR binding, have reduced PH in response to 
hypoxia (37). Although these mice may have reduced FGF signal-
ing, several factors may account for their contrasting response to 
hypoxia. First, perlecan-HS may affect the activity of other growth 
factors in addition to FGF. For example, perlecan is required for 
VEGF signaling in skeletal angiogenesis, developmental angio-
genesis, and VEGFR2 activation of human ECs (62, 63). Second, 
perlecan-HS–deficient mice have developmental defects that 
include a reduced percentage of αSMA-positive pulmonary vessels 
and reduced pericyte coverage of distal pulmonary vessels, which 
is in contrast with our EC-targeted FGFRs that have no change in 
caFGFR1 expression is induced at different time points after 
the initiation of hypoxia exposure.
We and others have reported that EC FGFR1 and FGFR2 are 
not necessary for vascular development or homeostasis, includ-
ing the maintenance of normal vascular barrier function (39, 40, 
41). Collectively, these studies suggest that under homeostatic 
conditions ECs are resistant to gain or loss of FGFR1/2 signaling. 
Further studies will be required to understand the basis of this 
resistance and how perturbations of homeostasis, such as injury 
or hypoxia, sensitize ECs to FGFR signaling. The absence of an 
effect of FGFR activation on unperturbed ECs also suggests that 
the EC FGFR1 signaling pathway may be a safe therapeutic target 
for the prevention of hypoxia-induced PH.
Figure 8. Effect of hypoxia and 
FGFR signaling on expression of 
the TGF-β–mediated endothe-
lial-mesenchymal transition 
pathway. RNA expression of 
components of the TGF-β path-
way during EndMT in lungs of 
hypoxia-exposed (A) FLK1-DCKO 
(n = 4) and (B) caFGFR1 mice (n 
= 4). Statistical significance was 
determined by 2-way ANOVA 
with Holm-Šídák multiple com-
parison test. All data are shown 
as the mean ± SEM. *P < 0.05, 
**P < 0.01. Closed circles, control 
mice in normoxia (nControl); open 
circles, control mice in hypoxia 
(hControl); closed squares, Flk1Cre; 
Fgfr1fl/fl; Fgfr2fl/fl mice in normoxia 
(nFLK1-DCKO) or caFGFR1 mice 
in normoxia (ncaFGFR1); open 
squares, Flk1Cre; Fgfr1fl/fl; Fgfr2fl/fl  
mice in hypoxia (hFLK1-DCKO) 
or caFGFR1 mice in hypoxia 
(hcaFGFR1).
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against hypoxia-induced PH. Fate 
mapping with reporter mice has 
facilitated the discovery of EndMT 
in many disease models. Qiao et al. 
found high levels of EC-lineage cells 
expressing αSMA and smooth mus-
cle myosin heavy chain in remod-
eled pulmonary arteries of mice 
with PH (65). In the mouse models 
presented here, loss of EC FGFR sig-
naling in vivo together with hypoxia 
exposure resulted in an increase in 
the number of smooth muscle cells 
of endothelial origin. Conversely, 
activation of FGFR signaling in 
ECs decreased the contribution of 
endothelium-originated cells to the 
smooth muscle layer, suggesting that 
FGFR signaling inhibits the EndMT 
process. Some of the EndMT pro-
cesses include loss of EC cell-cell 
contact, increased expression of 
Twist1, Snai1, Snai2, and Acta2, and 
decreased expression of Cdh5 and 
Pecam1 (19, 20, 66). Hence, we show 
that exposing our mice to hypoxia 
increased expression Tgfbr2 in vivo 
along with EndMT mediators Snai1, 
Snai2, and Twist1. We found that 
lack of EC FGFR signaling further 
augmented EndMT changes, and 
increased EC FGFR1 activity inhib-
ited this process. FGF2 can mod-
ulate TGF-β1 signaling by regulat-
ing ALK5 and TGF-βR2 expression 
(67) and TWIST1 further enhances 
TGF-βR2 expression and Smad2 
phosphorylation, resulting in 
decreased expression of EC mark-
ers (66, 68). Chen et al. also showed 
that inhibition of FGF signaling 
with a dominant negative mutant of 
FGFR1 or FRS2α increased TGF-β 
signaling (41). Hence, we asked 
whether EC FGFR activity modu-
lates TGF-β signaling in hypoxia- 
exposed mice. We demonstrated that loss of EC FGFR and hypoxia 
exposure increased Tgfbr2 expression and downstream Twist1 
expression. Consistent with these results, we showed that Tgfbr2 
expression was reduced when FGFR signaling was activated in 
the presence of hypoxia, resulting in decreased Smad2/3 phos-
phorylation. However, because FRS2 is also a critical regulator 
of VEGF signaling (69), further studies are warranted to deter-
mine the relative contributions of VEGFR and FGFR signaling to 
EndMT. Although the number of ECs expressing p-Smad2/3 in 
caFGFR1 mice was reduced, it remained slightly elevated com-
pared with normoxia controls. This suggests that EC FGFR may 
vascular wall thickening or neovascularization under normoxic 
conditions. Third, Chang et al. exposed female mice to 4 weeks 
of hypoxia, whereas we exposed male mice to 2 weeks of hypox-
ia, and we found a sex-specific difference in RVp when comparing 
male and female mice, with male mice showing lower RVp com-
pared with female mice (Supplemental Figure 3).
EndMT is an adaptive response that is involved in the patho-
genesis of several vascular diseases (21, 45, 64). Studies have 
shown that FGF-regulated TGF-β signaling can modulate End-
MT in a mouse model of atherosclerosis (31). Hence, we hypoth-
esized that EC FGFR signaling might reduce EndMT to protect 
Figure 9. p-Smad2/3 expression in pulmonary endothelial cells. (A and B) Visualization of p-Smad2/3  
(red) and endothelial cell (PECAM1, green) immunofluorescence. Arrowheads, p-Smad2/3+PECAM1+ double- 
positive endothelial cells; arrows, PECAM1+ singly positive endothelial cells. Scale bars: 25 μm and 20 μm 
(insets). Quantification of EndMT (right) showing the percentage p-SMAD2/3+PECAM1+ double-positive 
endothelial cells as a percentage of all PECAM1+ endothelial cells in (A) FLK1-DCKO and (B) caFGFR1 mouse 
lungs, respectively, n = 4. Statistical significance was determined by 2-way ANOVA with Holm-Šídák  
multiple comparison test. All data are shown as the mean ± SEM. **P < 0.01. Closed circles, control mice in 
normoxia (nControl); open circles, control mice in hypoxia (hControl); closed squares, Flk1Cre; Fgfr1fl/fl; Fgfr2fl/fl  
mice in normoxia (nFLK1-DCKO) or caFGFR1 mice in normoxia (ncaFGFR1); open squares, Flk1Cre; Fgfr1fl/fl; 
Fgfr2fl/fl mice in hypoxia (hFLK1-DCKO) or caFGFR1 mice in hypoxia (hcaFGFR1).
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doxycycline treatment, which increased VE-cadherin expression 
to enhance EC adherens junctions (74).
TGF-β signaling has been shown to regulate EndMT in ECs in 
vitro (29, 45) and inhibition of FGF signaling together with TGF-β 
stimulation can augment Smad2/3 phosphorylation (75). Thus, 
we asked whether TGF-β signaling was affected by gain or loss of 
EC FGF signaling in HPAECs cultured under hypoxic conditions. 
First, we showed that short-term (48 hour) inhibition of FGFR sig-
naling increased Tgfb2 expression in normoxia but had no effect 
on downstream signaling components. In the presence of hypoxia, 
FGFR inhibition with BGJ398 increased expression of Tgfb2 and 
downstream mediators and markers of EndMT. To determine the 
effect of FGF inhibition on chronic hypoxia, we exposed HPAECs 
to 14 days of hypoxia and showed that prolonged hypoxia increased 
only partially suppress TGF-β signaling, but that this is sufficient 
for PH phenotype rescue. SNAI1 and SNAI2 are known to mediate 
hypoxia-induced EndMT (70) and combined SNAI1 overexpres-
sion and TGF-β2 treatment markedly induced EndMT, resulting 
in endothelial and mesenchymal marker changes along with EC 
migration (71). In support of our findings that FGFR signaling reg-
ulated Snai1 and Snai2 expression, Cooley et al. and Medici et al. 
showed the EndMT is regulated by a TGF-β–activated Smad2/3/
SNAI2–dependent signaling pathway (72, 73). Collectively, our 
in vivo expression data show that FGFR signaling regulates the 
TGF-β/SMAD pathway–dependent expression of downstream 
EndMT mediators. We noted that the lack of change in Pecam1 
and Acta2 expression in doxycycline-treated hypoxia-exposed 
mice and their normoxia littermates may be due to the effect of 
Figure 10. Effect of FGFR inhibition on genes 
involved in TGF-β–mediated endothelial- 
mesenchymal transition in human pulmonary 
artery endothelial cells (HPAECs). Relative 
RNA expression of components of the TGF-β 
pathway and mesenchymal markers during 
EndMT in HPAECs exposed to hypoxia for (A) 
48 hours or (B) 14 days compared with controls 
in normoxia, with or without FGFR inhibitor 
BGJ398, n = 3. Statistical significance was 
determined by 2-way ANOVA with Holm-Šídák 
multiple comparison test. Closed circles, 
HPAECs in normoxia treated with vehicle; 
closed squares, HPAECs in normoxia treated 
with BGJ398; open circles, HPAECs in hypoxia 
treated with vehicle; open squares, HPAECs in 
hypoxia treated with BGJ398. (C) Relative RNA 
expression of Fgf2 and downstream FGF sig-
naling targets Etv4, Etv5, and Dusp6 in HPAECs 
exposed to 14 days of hypoxia compared with 
controls in normoxia, n = 3. Statistical signif-
icance was determined by 2-tailed, unpaired 
Student’s t test. *P < 0.01, **P < 0.05. All data 
are shown as the mean ± SEM.
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ECs can transdifferentiate in vitro when cultured on plastic or 
glass, we did not detect this in our cultures. This may be due to sev-
eral factors: HPAECs were cultured on gelatin-coated dishes using 
EC growth media, and dishes were subcultured at lower density 
to optimize for 80%–100% confluence at the end of 2 weeks. We 
observed that HPAECs that had undergone EndMT were localized 
in colonies spread out across the dish. Further studies would need 
to be conducted to determine if each colony was clonally propa-
gated. Collectively, these data show that, with FGF inhibition, 
HPAECs cultured in prolonged hypoxia can undergo EndMT.
To evaluate whether EndMT occurs in pulmonary conditions 
that may contribute to Group 3 PH, we assessed lung samples 
from patients with CPFE with documented elevated mean pul-
monary artery pressure (mPAP > 25 mmHg). We noted decreased 
Smad2/3 phosphorylation and elevated EndMT mediators. Nota-
bly, we found that Fgf2 and its downstream targets Etv4, Etv5, and 
Dusp6 were also elevated after 14 days of hypoxia, suggesting a 
negative feedback mechanism of FGF signaling during EndMT. 
DUSP6 is a negative feedback regulator of FGFR signaling (76, 77) 
and is also known to regulate EC inflammation via NF-κB–mediat-
ed ICAM-1 expression (78). This would suggest that the increased 
DUSP6 expression is a pro-EndMT response to hypoxia to nega-
tively regulate FGFR signaling and activate the EC inflammatory 
process. Previous studies demonstrated EndMT in vitro after 3–4 
days of hypoxia with human coronary artery ECs (79) and less than 
24 hours of hypoxia with bovine aortic ECs (24). In our system, we 
observed colonies of αSMA-expressing cells among HPAECs, indi-
cating EndMT in vitro after 2 weeks of hypoxia. Although primary 
Figure 11. Effect of FGFR  
inhibition on endothelial- 
mesenchymal transition in 
human pulmonary artery 
endothelial cells (HPAECs). 
(A) Representative images of 
CDH5 (red) and αSMA (green) 
immunofluorescence in HPAECs 
treated with FGFR inhibitor 
BGJ398 under hypoxic condi-
tions compared with controls in 
normoxia. Scale bar: 10 μm. (B) 
Quantification of the number 
of colonies of αSMA-positive 
cells per culture well in HPAECs 
treated with the FGFR inhibitor 
BGJ398 under hypoxic condi-
tions compared with controls 
in normoxia, n = 4–10. Closed 
circles, HPAECs in normoxia 
treated with vehicle; open circle, 
HPAECs in hypoxia treated 
with vehicle; closed squares, 
HPAECs in normoxia treated 
with inhibitor; open squares, 
HPAECs in hypoxia treated with 
inhibitor. (C) Representative 
Western blots and quantifica-
tion of p-Smad2/3 normalized 
to total Smad proteins, n = 5. (D) 
Representative Western blots 
and quantification of αSMA 
normalized to β-actin, n = 3. See 
complete unedited blots in the 
supplemental material. Statisti-
cal significance was determined 
by 2-way ANOVA with Holm-
Šídák multiple comparison test. 
All data are shown as the mean 
± SEM. *P < 0.05, **P < 0.01. (E) 
Proposed model showing FGF 
inhibition of hypoxia-stimulated 
TGF-β signaling in endothelial 
-mesenchymal transition.
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and EndMT. This suggests that TGF-β–mediated EndMT is only 
partially regulated by EC-caFGFR1 signaling or that other fac-
tors independent of EndMT contribute to vascular wall thicken-
ing in response to hypoxia.
Our studies show that loss of FGFR signaling in the endo-
thelium results in more severe Group 3 hypoxia-induced PH, 
which is in contrast to studies on Group 1 PH (PAH) that sug-
gest that FGFR signaling is pathologic (33, 34, 36) and that inhi-
bition of FGF2 activity is beneficial (33–35). Pulmonary ECs 
from PAH patients (PAH-ECs) exhibited higher FGF2 expres-
sion (34), increased FGF2 in the culture media, and increased 
survival and proliferation when treated with exogenous FGF2 
(33). When treated with PAH-EC–conditioned culture media, 
smooth muscle cells from PAH patients demonstrated increased 
proliferation (36). Downregulation of Apelin, miR-424, and 
FGFR signaling and increased TGF-β signaling in lung tissue from 
these patients. These data are consistent with our mouse model 
and in vitro experiments suggesting that activation of FGFR sig-
naling inhibits TGF-β signaling–induced EndMT. Collectively, 
these studies support a model in which FGFR signaling modulates 
hypoxia-induced EndMT, at least in part, by regulating TGF-β/
SMAD2/3 signaling (Figure 11E).
Expression of Fgf2 is increased after chronic hypoxia in vivo 
in mouse and patient samples and in vitro in HPAECs. In CPFE 
patients with physiologic changes consistent with PH, we noted 
decreased FGFR signaling. Yet, we also showed that constitutive 
FGFR1 signaling leads to reduced PH in mice. Although there 
was no PH in hypoxia-exposed caFGFR1 mice, we still observed 
increased vascular wall thickening in the larger proximal vessels 
(Figure 5C), consistent with moderately increased p-Smad2/3 
Figure 12. FGF signaling in lungs of 
patients with combined pulmonary  
fibrosis and emphysema. (A) Repre-
sentative immunofluorescence images 
showing expression of ETV5 (green) 
and CDH5 (red) in endothelial cells in 
lung tissue from patients with CPFE 
compared with normal lung tissue 
(control). Arrowheads, ETV5+CDH5+ 
double-positive endothelial cells; 
arrows, CDH5+ singly positive endo-
thelial cells. Scale bars: 25 μm and 
20 μm (insets). (B) Representative 
immunofluorescence images showing 
p-Smad2/3 (green) and CDH5 (red) 
expression in endothelial cells in lung 
tissue from patients with CPFE com-
pared with normal lung tissue (con-
trol). Arrowheads, p-SMAD2/3+CDH5+  
double-positive endothelial cells; 
arrows, CDH5+ singly positive endo-
thelial cells. Scale bars: 5 μm and 
20 μm (insets). (C) Quantification of 
ETV5+CDH5+ double-positive endo-
thelial cells in CPFE compared with 
control lungs, n = 5. (D) Quantification 
of p-SMAD2/3+CDH5+ double-positive 
endothelial cells in CPFE compared 
with control lungs, n = 5. Statistical sig-
nificance was determined by 2-tailed,  
unpaired Student’s t test. *P < 0.05. All 
data are shown as the mean ± SEM.
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Study approval. All studies performed were in accordance with the 
Institutional Animal Care and Use Committee at Washington Univer-
sity in St. Louis (protocol nos. 20160113 and 20190110). Mice were 
handled in accordance with standard use protocols, animal welfare 
regulations, and the NIH Guide for the Care and Use of Laboratory Ani-
mals (National Academies Press, 2011).
All human participants consented to donate their lung tissues 
for research under protocols approved by the Washington University 
Institutional Review Board (98-0510/201103213). Patient identifiers 
including name, age, sex, and ethnic group were concealed.
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miR-503 in PAH-ECs increased FGF2 and FGFR1 expression 
and pulmonary artery EC and VSM cell proliferation (35). Using 
the monocrotaline-induced model of PH in rats, Izikki et al. 
showed that 2 treatments with the VEGFR2 and FGFR1 inhib-
itor SU5402 reversed the PH effects (34). Our data showing 
that FGFR signaling is protective against hypoxia-induced PH 
suggests a divergent role for FGF signaling in a disease con-
text–dependent manner. However, these differences may also 
be due to the different animal models and that PAH-ECs may 
already be sensitized to PH changes compared with HPAECs 
isolated from normal lungs.
Hypoxia augments the Kruppel-like factor 4–dependent 
(KLF4-dependent) clonal expansion of VSM progenitors in pul-
monary arterioles (80). Increased FGF2 expression in PAH-EC–
conditioned media augments VSM cell proliferation (35). We 
showed that, after hypoxia exposure, FGF2 expression is increased 
in FLK1-DCKO mice and decreased in caFGFR1 mice. FGF-regu-
lated EndMT in hypoxia-exposed ECs may play a partial role in 
contributing to increased VSM in the medial layer. Increased para-
crine FGF2 expression may play a direct role in VSM cell prolifer-
ation. Further studies will be needed to determine the role of FGF 
signaling in chronic hypoxia–induced VSM cell proliferation.
We recognize that assessment of gene expression with RNA 
generated from whole lungs of hypoxia-exposed mice is a limita-
tion of this study. We considered fluorescence-assisted cell sorting 
to isolate ECs; however, the tissue would be exposed to normoxic 
conditions for several hours during tissue digestion and cell sort-
ing, and this process would not assess regional differences in ECs. 
Furthermore, EC FGF2 expression is amplified by a HIF1α-depen-
dent pathway (38), and chronic but not short-term hypoxic induc-
tion of HIF1α in HUVECs is FGF2 dependent. Further studies are 
needed to investigate the role of FGF2-HIF1α interactions during 
EndMT under chronic hypoxic conditions. Because FGF2-HIF1α 
crosstalk can mediate angiogenesis in tumor models (81), addi-
tional studies will be needed to determine whether chronic hypox-
ia induces a similar FGF-HIF1α signaling interaction.
These findings may have important clinical implications for pre-
clinical and clinical studies aimed at preventing patients at risk from 
developing chronic hypoxia-induced PH or treating patients with 
hypoxia-induced PH. There is a growing recognition of the clinical 
importance of hypoxic lung disease. The observation that endoge-
nous FGFR signaling may limit the progression of hypoxia-induced 
PH and that further activation of EC FGFR signaling may prevent 
key pathological features of hypoxia-induced PH opens potential 
avenues to explore biological therapies for this family of diseases.
Methods
Animal care and use. Mice were group housed in a specific pathogen–
free facility with littermates, in breeding pairs, or in a breeding harem 
(2 females to 1 male), with food and water provided ad libitum. 
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